The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Acacia Pharma Group plc
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
Thiele Kaolin Company
Advised Thiele Kaolin Company, a miner and processor of kaolin clay, on a range of strategic options, resulting in a leveraged recapitalization and special dividend
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Ibbotson Associates
Advised Ibbotson Associates on its sale to Morningstar Inc. for $83 million
BioD, LLC
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
Publications International, Ltd. Children’s Division
Advised Publications International, a leading consumer book publisher, on the sale of its Children’s Division to Jiangsu Phoenix Publishing and Media Corporation Limited
Abacus Health Products, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
Biotage (Biosystems division)
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
Sye business area of Net Insight AB
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
Acacia Pharma Group plc
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
Journal Communications, Inc.
Advised the Board of Directors of Journal Communications, Inc., a diversified media company with newspaper and broadcasting interests, in connection with the repurchase of 100% of the issued and outstanding shares of its Class C Common Stock from successors to the Company’s founding family
Money Controls (subsidiary of Coin Acceptors, Inc.)
Advised Coin Acceptors, Inc. (“CoinCo”), a privately-owned US-based manufacturer of payment solutions for the automated point-of-sale industry, on the sale of its UK-based Money Controls subsidiary to Crane Co., a diversified manufacturer of highly engineered industrial products
Beattie McGuinness Bungay Ltd.
Advised Cheil Worldwide, Inc, South Korea’s largest marketing agency, on the acquisition of Beattie McGuinness Bungay Ltd, a leading independent UK advertising agency
Golf Digest
Advised Condé Nast on the sale of Golf Digest, a leading golf media brand, to Discovery
Netrics Digital Infrastructure
Advising NorthC, the largest regional data center provider in the Netherlands, on their agreement to acquire the data centers and connectivity services of Netrics in Switzerland
Heartscape Technologies, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US Department of the Treasury
Advised the United States Department of the Treasury on the management and disposition of its common shares of AIG
Dillard's, Inc. (Credit Card Assets)
Advised Dillard’s, Inc. on a strategic alliance relating to its credit card business with Wells Fargo & Company
Global Television
Advised Catalyst Investment Managers on the sale of its portfolio company Global Television, Australia’s largest provider of outsourced broadcasting and video production services, to NEP Inc., a leading provider of total broadcast solutions in the US, UK and Brazil. NEP is majority-owned by private funds managed by Crestview Partners
Brides
Advised Condé Nast on the sale of Brides, a leading wedding and bridal brand, to IAC
Unison Site Management
Advised Ardian US LLC, on its investment in wireless infrastructure asset aggregator Unison Site Management
Pfizer Inc. Consumer Health Business
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
Cosmetic applications endolysin
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100